Modifying effect of colicin on experimental Shigella keratoconjunctivitis

Area of Science:

• Microbiology
• Bacteriology
• Infectious Diseases

Background:

• Shigella sonnei is a significant human pathogen causing bacillary dysentery.
• Colicins are bacteriocins produced by Escherichia coli that exhibit antimicrobial activity against related strains.
• Investigating natural antimicrobial agents for controlling bacterial infections is crucial.

Purpose of the Study:

• To evaluate the efficacy of colicinogenic bacteria and purified colicin in controlling Shigella sonnei infection.
• To assess the impact of colicin treatment on disease progression and bacterial load in an animal model.

Main Methods:

• Utilizing the guinea pig conjunctiva as an experimental model for Shigella sonnei infection.
• Treating infected conjunctivae with a colicinogenic Escherichia coli strain or purified colicin.
• Comparing bacterial counts and disease development in treated versus untreated S. sonnei-infected guinea pigs.
• Testing the effect of colicin treatment on colicin-resistant S. sonnei strains.

Main Results:

• Treatment with colicinogenic E. coli or colicin significantly reduced the number of S. sonnei cells in infected guinea pig conjunctivae.
• Reduced S. sonnei bacterial load was correlated with the absence of disease symptoms.
• A noncolicinogenic E. coli strain did not affect disease production.
• Colicin treatment had no impact on disease or bacterial numbers when using a colicin-resistant S. sonnei strain.

Conclusions:

• Colicinogenic bacteria and colicin demonstrate significant potential as therapeutic agents against Shigella sonnei infections.
• The efficacy of colicin treatment is strain-specific, highlighting the importance of bacterial resistance mechanisms.
• This study supports the use of colicin-based strategies for controlling Shigella infections.